Salvage Ovarian FANG™ Vaccine + Bevacizumab

Clinical Trial Summary

This is a Phase II study of Vigil™ autologous tumor cell vaccine integrated with bevacizumab. All patients will have had Vigil™ prepared and stored from initial primary surgical debulking. Patients meeting eligibility criteria will receive Vigil™ 1.0 x 10e7 cells/intradermal injection once every 4 weeks and bevacizumab 10 mg/kg intravenously every 2 weeks.

See also
Status	Clinical Trial	Phase
Completed	`NCT01010126` - Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer	Phase 2
Terminated	`NCT00899093` - YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy
Completed	`NCT00301756` - Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors	Phase 2
Completed	`NCT00262847` - Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	Phase 3
Recruiting	`NCT01000259` - Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer	N/A
Completed	`NCT00066456` - Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer	Phase 1
Withdrawn	`NCT00551265` - Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy	N/A
Completed	`NCT03188432` - Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Phase 2
Completed	`NCT03297489` - Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer	Early Phase 1
Withdrawn	`NCT00053235` - Research Study in Patients With Advanced Ovarian Epithelial Cancer	N/A
Completed	`NCT00194714` - Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab	Phase 1/Phase 2
Terminated	`NCT02441140` - Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis	N/A
Completed	`NCT01131234` - Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT05659381` - Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer	Phase 3
Terminated	`NCT00003532` - Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer	Phase 2
Completed	`NCT01522820` - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors	Phase 1
Not yet recruiting	`NCT06315270` - To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer
Withdrawn	`NCT02872519` - PET Imaging of Ovarian Carcinoma With 18F-FSPG	Early Phase 1
Withdrawn	`NCT02567396` - Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction	Phase 1
Withdrawn	`NCT02470559` - Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent	Phase 1

NCT number	NCT01551745
Study type	Interventional
Source	Gradalis, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	March 2012
Completion date	April 2016

Salvage Ovarian FANG™ Vaccine + Bevacizumab

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms